About the organization
Basic details : The European Patients’ Academy (EUPATI) is a pan-European project implemented as a public-private partnership by a collaborative multi-stakeholder consortium from the pharmaceutical industry, academia, not-for-profit, and patient organisations. EUPATI was started, developed and implemented as a flagship project of the Innovative Medicines Initiative (http://www.imi.europa.eu/), and continues to be led by the European Patients’ Forum. EUPATI has already trained 96 patient experts on medicines development, clinical trials, medicines regulations, health technology assessment. Additionally, EUPATI provides the Toolbox on Medicine Development which has been used by more than 250.000 individuals, and coordinates a network of national platforms in 18 countries. EUPATI focuses on education and training to increase the capacity and capability of patients to understand and contribute to medicines research and development and also improve the availability of objective, reliable, patient-friendly information for the public.Patient involvement in R&D, strengthened by EUPATI's training and communication activities and informational resources, will make sure that patients priorities and needs are at the center in all research and development work on safe and effective new treatments, ultimately improving patient outcomes.
Mission : The European Patients’ Academy (EUPATI) is a pan-European project implemented as a public-private partnership by a collaborative multi-stakeholder consortium from the pharmaceutical industry, academia, not-for-profit, and patient organisations. EUPATI was started, developed and implemented as a flagship project of the Innovative Medicines Initiative (http://www.imi.europa.eu/), and continues to be led by the European Patients’ Forum. EUPATI has already trained 96 patient experts on medicines development, clinical trials, medicines regulations, health technology assessment. Additionally, EUPATI provides the Toolbox on Medicine Development which has been used by more than 250.000 individuals, and coordinates a network of national platforms in 18 countries. EUPATI focuses on education and training to increase the capacity and capability of patients to understand and contribute to medicines research and development and also improve the availability of objective, reliable, patient-friendly information for the public.
Vision : Patient involvement in R&D, strengthened by EUPATI's training and communication activities and informational resources, will make sure that patients priorities and needs are at the center in all research and development work on safe and effective new treatments, ultimately improving patient outcomes.
Organization primary focus : Patient engagement
Contact information
| Website | http://www.eupati.eu |
|---|---|
| Address | European Patients' Forum, 31 Rue du Commerce, 1000 - Brussels, BE |
| Contact us for | General partnerships , Good practice sharing , Opportunities for patient engagement collaborations , Speaking opportunities , Involving patient experts |
| Organization main contact email | info@eupati.eu |
People
Jan Geissler
Co-Founder
Munich, Germany
PFMD / Patvocates / Leukemia Patient Advocates Foundation / EUPATI
Initiatives
Resources
Commitments
Endometriosis advocate and Eupati fellow, Switzerland
Consulting with patients is something relatively new and radical. To turn it into something fruitful, creative, positive and productive, we will all need to communicate clearly and considerately.
Work in progress
Endometriosis advocate and Eupati fellow, Switzerland
Co-creation is where it is at. In the past, the lion share of investment in R&D was wasted (85%: redundant, inconclusive, duplicated or unpublished) and extraordinary numbers of trials failed or were incomplete (97%). What was missing? Patient collaboration, for starters. By co-creating, we can identify what patients actually need, value and want. Let's help meet public health needs by sharing our expertise.
Work in progress
Endometriosis advocate and Eupati fellow, Switzerland
I aim to listen to all parties involved in medicines development: including patients, pharma, and academia. We need to listen to one another, paying close attention one another's needs and ambitions in order to achieve goals that are beneficial to all of us and to society at large.
Work in progress